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Background: This study retrospectively compared the continuous epidural infusion of morphine 
with a single epidural injection of extended-release morphine for postoperative pain control 
after arthroplasty.
Methods: Medical records were reviewed for subjects who had total knee or hip arthroplasty 
(THA) under spinal anesthesia and received either a continuous epidural infusion of morphine 
(Group EPID; n = 101) or an extended-release epidural morphine (Group EREM; n = 109) for 
postoperative pain. Data were collected for three postoperative days (POD) on: pain scores; 
supplemental opioids; medications for respiratory depression, nausea, and pruritus, and distance 
ambulated during physical therapy.
Results: Pain scores were similar until subjects were transitioned to another analgesic approach 
on POD 2; after that time, pain scores increased in Group EPID, although they decreased in 
Group EREM. Supplemental opioids were used more on POD1 in Group EREM than in Group 
EPID, although time to first opioid and total daily morphine equivalents were similar. Naloxone 
and antiemetics, not antipruritics, were used more in Group EREM. Distance ambulated after 
THA was greater in Group EREM than in Group EPID.
Conclusions: These results suggest that EREM is associated with better postoperative ambu-
lation and analgesia during the transition to oral or intravenous analgesics, although a higher 
incidence of side-effects was evident.
Keywords: continuous epidural morphine infusion, extended-release epidural morphine, lower 
extremity arthroplasty, ambulation, postoperative pain, side-effects
Introduction
Total knee arthroplasty (TKA) and total hip arthroplasty (THA) are considered 
  effective treatments for end-stage joint deterioration due to osteoarthritis or 
  rheumatoid arthritis.1,2 Data from the National Hospital Discharge Survey indicates 
that in the period between 2003–2004, 428,000 knee replacement and 282,000 
non-fracture-related hip replacement operations were conducted in the United States, 
and those numbers are expected to rise as the population ages.3,4 Early intense physical 
therapy is instrumental for postoperative recovery and rehabilitation after both TKA 
and THA;5,6 however, severe postoperative pain often interferes with early physical 
therapy and decreases patients’ quality of life.7 The side-effects associated with many 
analgesic techniques, such as emesis and excessive sedation, can also compromise 
early physical therapy and rehabilitation.8Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Multiple studies have investigated the effectiveness of dif-
ferent analgesic techniques for lower extremity arthroplasty, 
including intravenous, regional and neuraxial approaches.1,2 Of 
the neuraxial modalities, both continuous epidural infusion of 
morphine and a single epidural injection of extended-release 
morphine, a lipid encapsulated preparation of morphine, are 
effective for pain control after TKA and THA.9–13 However, 
few studies have directly compared these two pain manage-
ment approaches, in terms of pain control, side-effects and 
ambulation after arthroplasty.
The aim of the present study was to retrospectively 
compare continuous epidural infusion of morphine with a 
single epidural injection of extended-release morphine in 
the 72 hours after THA or TKA. The time period studied 
included postoperative days 1–2 (POD 1–2), during which 
time the continuous infusion was in place and the extended-
release morphine was active,12 and POD 3, after patients were 
transferred to oral or intravenous analgesics; this allowed 
for an assessment of pain management during the transition 
of care. The primary outcomes were analgesia, side-effects 
(respiratory depression, nausea, pruritus) and ambulation.
Materials and methods
This study was approved by the Institutional Review Board 
at the University of North Carolina at Chapel Hill.
study design and subjects
A retrospective cohort design was used. Medical records 
were reviewed for 401 subjects who underwent primary 
unilateral THA or TKA, under the care of the same two 
surgeons, between May 2005 and April 2006. Medical 
records were included for further review (n = 210) if subjects 
received subarachnoid bupivacaine as the primary anes-
thetic, followed by either a continuous epidural infusion of 
40 µg/mL morphine with 0.1% bupivacaine (Group EPID, 
n = 101); or a single-dose epidural injection of extended-
release morphine (DepoDur®; EKR Therapeutics, San 
Diego, CA, USA) (Group EREM, n = 109) as the primary 
therapy for postoperative pain management. Other factors, 
such as the use of supplemental anesthetics, postoperative 
analgesics, or adjustments in the continuous epidural infu-
sion were not taken into consideration as part of the inclu-
sion process. Medical records were excluded from further 
review (n = 191) if subjects received any other primary 
form of anesthesia, such as general anesthesia, or any other 
primary approach to postoperative pain management. The 
subarachnoid dose of bupivacaine averaged 17.37 ± 0.53 mg 
(mean ± standard error of the mean [SEM]). The epidural 
infusion rate in Group EPID was dictated by the Acute 
Pain Service, and the epidural catheter was removed on 
postoperative day 2, as per routine postoperative manage-
ment. The dose of extended-release morphine averaged 
11.09 ± 0.23 mg (mean ± SEM), and was active for up to 
48 hours after epidural injection.12 Nineteen subjects (18.8%) 
in Group EPID and 3 subjects (2.8%) in Group EREM were 
transitioned to intravenous patient-controlled analgesia; the 
remaining subjects in each group were transitioned to oral 
or intravenous analgesic boluses.
Primary outcomes and data collection
Medical records (anesthesia record, post anesthesia care unit 
[PACU] and floor nursing charts, physical therapy records) 
were the primary data source. Data were collected on basic 
demographic and procedural characteristics, including age, 
sex, height, weight, procedure and indication. Data were 
then collected with regard to three primary postoperative 
outcomes: analgesia, side effects, and ambulation. Data 
were collected on the immediate postoperative period PACU, 
over PODs 1 and 2, the period during which the continuous 
EPID and the EREM are active, and for POD 3, after the 
two groups were transitioned to oral or intravenous anal-
gesia. Data on analgesia were obtained by recording the 
maximum pain score on an 11-point numerical rating scale 
(NRS) ranging from 0 (no pain) to 10 (worst pain imaginable) 
recorded by nurses in the PACU and during each 12-hour 
nursing shift over POD 1–3. Also data was collected for the 
use of supplemental opioids (drug, dose, time to first use). 
Data on side-effects were obtained by recording whether 
opioid antagonists (naloxone), antiemetics (ondansetron, 
promethazine) or antipruritics (diphenhydramine, loratadine, 
nalbuphine) were administered; these measures were used as 
surrogates for respiratory depression, nausea, and pruritus, 
respectively. Physical therapy records were used to collect 
data on the maximum distance ambulated (in feet) over POD 
1–3 during daily physical therapy sessions.
statistical analysis and sample  
size calculation
SPSS (version 15; SPSS, Inc. Chicago, IL, USA) was used 
for statistical analysis and Sigma Plot (version 10; SPSS, Inc.) 
was used for graphics. For analysis, doses of each   supplemental 
opioid were converted to equivalents of 10 mg intravenous 
morphine, using the conversion table provided by Gustein 
and Akil14 for hydrocodone, oxycodone and propoxyphene, 
and the conversion table provided by Dhesi and Hurley15 
for fentanyl and hydromorphone. The total daily morphine Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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equivalents that were administered were calculated for 
each subject by summation over each postoperative day. 
Opioid antagonists, antiemetics and antipruritics were 
treated as binary variables (administered or not adminis-
tered). NRS pain scores and the distance ambulated were 
treated as continuous variables. Body mass index (BMI) was 
calculated treated as a continuous variable. Demographic 
variables, clinical characteristics, time to first postopera-
tive opioid use and naloxone administration were compared 
between groups using Chi square analysis (for categorical 
data) or Student’s t-test (for continuous variables). General-
ized linear models were used to determine if pain scores, 
side-effects and ambulation differed between groups and 
over time, with main effects of group and time and a group 
× time interaction included in the model. Procedure type 
(THA or TKA) was included as a covariate in the analysis 
to control for any difference in outcome between the two 
groups. A post hoc Fisher’s Least Squares Difference test was 
used to compare group differences at specific time points. 
The ambulation data were analyzed overall and stratified by 
type of operation. The data were fairly complete, with pain 
scores complete for between 187 (89.0%) and 206 (98.1%) 
subjects, and physical therapy notes complete for between 
193 (91.9%) and 203 (96.7%) subjects, depending on the 
time point. Data on drug administration were complete for 
all subjects. The generalized linear model used an estimation 
algorithm to handle missing data points; the other statistical 
tests excluded missing variables. The significance level was 
set at α = 0.05.
Assuming a 2-point difference (± 2 standard devia-
tions) in the NRS score between Groups EREM and EPID, 
then to achieve 90% power, with α = 0.05, an estimated 
22 subjects per treatment group were required, for a total 
of n = 44. The incidence of severe postoperative respiratory 
depression after continuous epidural morphine/bupivacaine 
is not established, although a 1994 study reported a rate of 
0.07% for cancer patients.16 Assuming the true proportion 
of adverse events for Group EPID is 0.1% and that for 
Group EREM is 8%,9–11 then to achieve 80% statistical 
power, with α = 0.05, an estimated 97 subjects per group 
were required, for a total of 194. Data were collected on 
210 subjects in the current study, with 109 in Group EREM 
and 101 in Group EPID.
Results
Cohort characteristics
Groups EPID and EREM were similar with regard to the 
proportion of females, the average BMI and the   proportion 
of THA and TKA operations (Table 1). Subjects in 
Group EREM were, however, 6 years older on average, than 
subjects in Group EPID (P , 0.01; Table 1).
Analgesia
Pain scores on arrival to the PACU were low and aver-
aged 0.99 ± 0.18 (mean ± SEM). PACU pain scores did 
not change over the following two hours and were similar 
in both Group EPID and Group EREM (data not shown). 
Pain scores after arrival to the floor (POD 0) and for the 
morning and afternoon of POD 1 through 3 are shown 
for Groups EPID and EREM in Figure 1. A significant 
group × time interaction (P , 0.01) was apparent, meaning 
that group differences emerged over time. A post hoc analy-
sis showed that pain scores were higher in Group EPID than 
in Group EREM on the afternoon of POD 2 (P , 0.05), the 
morning of POD 3 (P , 0.05) and the afternoon of POD 3 
(P , 0.07). Pain scores did not differ between Group EPID 
and Group EREM during the period when the epidural 
catheter was in place and the EREM was active (ie, POD 0 
through to the morning of POD 2).
The supplemental IV or oral opioids that were adminis-
tered to subjects were fentanyl, morphine, hydromorphone, 
oxycodone, oxycodone/acetaminophen, hydrocodone/
acetaminophen, and propoxyphene/acetaminophen. Time 
to the first postoperative opioid averaged 112 ± 9 minutes 
(mean ± SEM) and did not differ between groups. Supple-
mental postoperative opioid use increased over time in both 
groups (P , 0.0005; Figure 2), and a significant group × 
time interaction was evident (P , 0.0005). A greater pro-
portion of subjects received opioids on POD 1 in Group 
EREM than in Group EPID (P , 0.0005), although a 
smaller proportion of subjects received opioids on POD 2 
and 3 in Group EREM than in Group EPID (P , 0.05 for 
POD 2; P , 0.06 for POD 3). For those subjects that received 
Table 1 Cohort characteristics
Group EPID 
(n = 101)
Group EREM 
(n = 109)
P valuea
Demographics
- Age (years) 61.26 (1.26) 67.12 (1.39) P , 0.01
- sex-Female  60 (59.4) 75 (68.8) n.s.
- BMi 30.21 (0.67) 29.01 (0.50) n.s.
Procedure
- Total hip Arthroplasty 
- Total Knee Arthroplasty
41 (40.6) 
60 (59.4)
55 (50.5) 
54 (49.5)
n.s.
Notes:  agroups ePiD and eReM were compared using student’s t-test or Chi 
square analysis. Values are mean (± seM) or n (%).
Abbreviations: group ePiD received a continuous epidural infusion of morphine. 
group eReM received a single epidural injection of extended-release morphine. 
seM, standard error of mean; n, number; BMi, body mass index.Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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supplemental opioids, the total daily morphine equivalents 
that were   administered per subject averaged 8.89 ± 1.12 mg 
(mean ± SEM) in the PACU, 16.96 ± 1.44 mg on POD 
0–1, 13.61 ± 0.77 mg on POD 2, and 12.64 ± 1.01 mg on 
POD 3. These values did not differ between Groups EPID 
and EREM.
side effects
One subject (1.0%) in Group EPID received naloxone for 
respiratory depression, whereas five subjects (4.6%) in Group 
EREM received naloxone, although the difference was not 
significant (P = 0.2). Rates of antiemetic use (Figure 3) 
decreased over time in both groups (P , 0.0005). A greater 
proportion of subjects received antiemetics in the PACU 
in Group EREM than in Group EPID (P , 0.01). Rates of 
antiemetic use over POD 1–3 did not differ between the two 
groups.
Rates of antipruritic use (Figure 4) varied over time 
(P , 0.0005), with the highest rates on POD 1. Antipruritic 
use was similar in Groups EPID and EREM.
Ambulation
The distance that subjects walked during physical therapy 
increased over time (P , 0.0005) (Figure 5A) and Group 
EREM showed better ambulation than Group EPID at all time 
points (P , 0.05). However, when subjects were stratified by 
type of procedure (THA versus TKA), the group difference 
was found only in the THA subset (P , 0.05; Figure 5B). 
For subjects undergoing TKA (Figure 5C), ambulation was 
similar in Groups EREM and EPID.
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Figure 1 Pain scores (mean ± seM) after lower extremity arthroplasty.
Notes: Pain scores were higher in group ePiD than in group eReM from POD 2 PM through POD 3 PM (P , 0.05 for POD 2 PM and POD 3 PM; P , 0.06 for POD 3 PM).
Abbreviations: group ePiD received a continuous epidural infusion of morphine; group eReM received a single epidural injection of extended-release morphine; PACU: 
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Figure 2 Percentage of subjects receiving postoperative opioids.
Notes:  A  greater  proportion  of  subjects  in  group  eReM  received  opioids  on 
POD 1 than in group ePiD (P , 0.0005), although a smaller proportion of subjects 
in group eReM received opioids on POD 2 (P , 0.05) and POD 3 (P , 0.06) than 
in group ePiD.
Abbreviations: group ePiD received a continuous epidural infusion of morphine; 
group eReM received a single epidural injection of extended-release morphine; 
PACU, post anesthesia care unit; POD, postoperative day.Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
275
Continuous infusion versus single injection of epidural morphine for arthroplasty
The current results identified an “analgesic gap” among 
patients who received a continuous epidural infusion of mor-
phine. An analgesic gap is defined as a decrease in analgesic 
effectiveness during the period of transition between pain 
management modalities and this can result from a number 
of different factors.17–20 In the current study, the analgesic 
gap might be the result of a breakdown in the “system”, as 
pain management responsibilities were transferred from the 
Acute Pain Service to the Orthopedic Service after the con-
tinuous epidural infusion was discontinued and the epidural 
catheter removed. An analgesic gap did not occur among 
patients who received extended-release epidural morphine, 
perhaps because pain management responsibilities were 
with the Orthopedic Service throughout the study period. 
Communication failures occur frequently among health care 
providers and are a common source of adverse events, includ-
ing such analgesic gaps.18,21 Alternative explanations for the 
analgesic gap after discontinuation of the epidural infusion 
include delays in implementing drug orders, rebound pain or 
even opioid-induced hyperalgesia.22 A follow-up study has 
been implemented to identify the cause(s) of the analgesic 
gap at our institution.
In terms of side effects, subjects who received 
  extended-release epidural morphine had higher rates of 
  nausea and respiratory depression than subjects who received 
a continuous epidural infusion of morphine. In the current 
study, the estimated incidence of respiratory depression after 
extended-release epidural morphine was close to 5%. Cases 
of respiratory depression requiring treatment with a narcotic 
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Figure 4 Percentage of subjects receiving postoperative antipruritics.
Notes:  The  proportion  of  subjects  receiving  antipruritics  postoperatively  was 
similar in groups eReM and ePiD. 
Abbreviations: group ePiD received a continuous epidural infusion of morphine; 
group eReM received a single epidural injection of extended-release morphine; 
PACU, post anesthesia care unit; POD, postoperative day.
Discussion
The present study aimed to retrospectively compare 
  continuous epidural infusion of morphine with a single 
  epidural injection of extended-release morphine (Depo-
Dur®) with regard to postoperative pain control, side-effects 
and ambulatory function. The time to first postoperative 
opioid and the total daily morphine equivalents that were 
  administered per subject were similar in the two groups. 
Postoperative pain scores were also similar in the two groups 
and decreased over time until patients were transitioned to 
oral or intravenous analgesics; at which point pain scores 
increased among subjects who received a continuous epidu-
ral infusion of morphine, yet continued to decrease among 
subjects who received extended-release epidural morphine. 
Rates of pruritus, as measured by antiemetic administra-
tion, were similar in the two groups, although subjects who 
received extended-release epidural morphine had higher 
rates of respiratory depression and nausea, as measured 
by naloxone and antiemetic administration, respectively. 
Subjects who received extended-release epidural morphine 
after THA, but not TKA, had better postoperative ambula-
tion than subjects who received a continuous epidural infu-
sion of morphine. Collectively, these results suggest that 
compared to patients who receive a continuous epidural 
infusion of morphine for postoperative pain, patients who 
receive extended-release epidural morphine are more eas-
ily transitioned to oral or intravenous analgesics, although 
they also experience higher rates of nausea and respiratory 
depression.
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Figure 3 Percentage of subjects receiving postoperative antiemetics.
Notes: A greater proportion of subjects in group eReM received antiemetics in the 
PACU than in group ePiD (P , 0.01), but the two groups did not differ in antiemetic 
use over POD 1–3.
Abbreviations: group ePiD received a continuous epidural infusion of morphine; 
group eReM received a single epidural injection of extended-release morphine; 
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antagonist have been reported in 4%–8% of subjects receiving 
extended-release epidural morphine (DepoDur®) for total 
joint replacement surgery.10–12 Because of the risk of respira-
tory depression, the continuous monitoring of vital signs is 
recommended for all patients who receive   extended-release 
epidural morphine.23–25 The current results support this 
recommendation.
Ambulatory function was greater among subjects who 
received extended-release epidural morphine than among 
those who received a continuous epidural infusion of mor-
phine, perhaps because of the ease of ambulation without 
the infusion pump. However, the effect was found only in 
the THA subset. The reason(s) why similar results were not 
found in the TKA subset is unclear, although it might reflect 
the different approaches taken by physical therapists for 
rehabilitation after THA versus TKA.6 For instance, patients 
who undergo THA may be more encouraged to ambulate 
postoperatively than patients who undergo TKA.
Limitations
Several limitations of this study should be considered when 
interpreting the results. First, this was a retrospective study 
and as such, it is vulnerable to several forms of bias. Second, 
the primary data sources were nursing and physical therapy 
records, and nurses and physical therapists were not specifi-
cally trained for data collection, making measurement error 
possible. Third, the two groups were not identical in their 
demographic characteristics. In particular, subjects in Group 
EREM were older than subjects in Group EPID, and this age 
difference might have influenced the results. Fourth, factors 
other than pain are known to influence ambulation after TKA 
and THA, including numbness, weakness, hypovolemia and 
other factors that were not examined. Fifth, although TKA 
and THA are relatively standardized procedures and the 
same two surgeons performed the operations throughout 
the study period, variations in surgical technique could 
have been introduced confounding the data. Sixth, baseline 
pain scores are known to influence postoperative pain26 and 
this was not accounted for in the present study. Finally, the 
two pain management approaches that were compared were 
not strictly standardized and variation in technique existed 
within the groups.
Conclusions
In summary, continuous epidural infusion of morphine 
and single epidural injection of extended-release mor-
phine provided similar levels of pain control, although the 
transition to oral or intravenous analgesics resulted in an 
analgesic gap among subjects in the continuous epidural 
infusion group. This analgesic gap is likely related to a 
system issue, rather than the analgesic technique itself. 
Patients who received extended-release epidural morphine 
experienced higher levels of respiratory depression and 
nausea, although a better return to function, at least after 
THA. Further prospective studies comparing these two pain 
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management approaches are warranted before treatment 
recommendations can be made.
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